Suggested remit: To appraise the clinical and cost effectiveness of alectinib within its marketing authorisation as adjuvant treatment of ALK-positive non-small-cell lung cancer (NSCLC).
Status In progress
Technology type Medicine
Decision Selected
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Process STA Standard
ID number 6368

Provisional Schedule

Committee meeting: 1 03 October 2024
Expected publication 11 December 2024

Project Team

Project lead Kate Moore

Email enquiries

External Assessment Group BMJ Technology Assessment Group (BMJ-TAG), BMJ


Companies sponsors Roche (alectinib)
Others Department of Health and Social Care
  NHS England
Patient carer groups Roy Castle Lung Cancer Foundation
Professional groups Association of Cancer Physicians
  British Thoracic Oncology Group
  Cancer Research UK
  Royal College of Physicians
  Royal College of Radiologists
Comparator companies Bristol Myers Squibb (paclitaxel)
  Merck Sharp & Dohme UK (pembrolizumab)
  Pfizer (cisplatin, carboplatin, docetaxel, oxaliplatin, paclitaxel, pemetrexed)
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health - Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  Scottish Medicines Consortium
  Welsh Government
  Welsh Health Specialised Services Committee
Relevant research groups Institute of Cancer Research


Key events during the development of the guidance:

Date Update
05 March 2024 Invitation to participate
22 January 2024 - 05 February 2024 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6368
22 January 2024 In progress. Scoping commencing
24 October 2023 Awaiting development. Status change linked to Topic Selection Decision being set to Selected

For further information on our processes and methods, please see our CHTE processes and methods manual